Home › Atopic Dermatitis (Eczema) › NCT07223697

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study

Parent Clinical Trial-Specific Criteria:

* Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved =\> EASI50 response from study baseline

Exclusion Criteria:

* Evidence of other skin conditions that would interfere with the assessment of AD
* Withdrawal of consent and/or premature discontinuation from parent study
* Any permanent discontinuation of study drug in parent study
* History of severe allergic reaction or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of Afimkibart

About the study

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

What is being tested

• Afimkibart (drug)

Sponsor: Hoffmann-La Roche · Participants: 120 · Started: Jan 8, 2026

Contact the study team

• Reference Study ID Number: CS45943 https://forpatients.roche.com/ No attachments to email below. · Phone: 888-662-6728 (U.S. Only)

Official record on ClinicalTrials.gov — NCT07223697

Locations in the U.S.

Conditions

• Atopic Dermatitis (Eczema)

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.